NCT06440005View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 22, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2027

Conditions
CancerAdvanced CancerLocally Advanced CarcinomaMetastatic Solid TumorBreast CancerProstate CancerColorectal CancerPancreatic CancerLiver CancerAngiosarcomaSolid Tumor
Interventions
DRUG

AGX101

Antibody Drug Conjugate

Trial Locations (3)

22031

RECRUITING

NEXT Oncology, Fairfax

37203

RECRUITING

Sarah Cannon Research Center, Nashville

78229

RECRUITING

NEXT Oncology, San Antonio

All Listed Sponsors
lead

Angiex, Inc.

INDUSTRY